Pfizer publishes transcript of Pflash Live from ADA: Spotlight on Obesity event

Pfizer

Pfizer

PFE

0.00
  • Pfizer hosted a Pflash Live event at the American Diabetes Association 86th Scientific Sessions in New Orleans, attended by the Chief Investor Relations Officer, the Chief Internal Medicine Officer, and the US Primary Care President.
  • Management positioned berobenatide as an investigational first-in-class monthly GLP-1 peptide, targeting weight loss comparable to tirzepatide with favorable GI tolerability.
  • Phase 2b VESPER-3 showed placebo-corrected weight loss up to 12.3% at week 28 on 4.8 mg monthly; VESPER-2 showed up to 9.5% in diabetes.
  • Extension data for 2.4 mg weekly showed about 16% mean weight loss at 32 weeks; modeling projected similar 72-week loss to tirzepatide.
  • Phase 3 plan: 10 trials advancing in 2026; weekly approvals targeted in 2028 with monthly as a fast follow, including a global switch study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.